This is a preprint.
Environmental and Structural Factors Associated with Bacterial Diversity in Household Dust Across the Arizona-Sonora Border
- PMID: 37841844
- PMCID: PMC10571632
- DOI: 10.21203/rs.3.rs-3325336/v1
Environmental and Structural Factors Associated with Bacterial Diversity in Household Dust Across the Arizona-Sonora Border
Update in
-
Environmental and structural factors associated with bacterial diversity in household dust across the Arizona-Sonora border.Sci Rep. 2024 Jun 4;14(1):12803. doi: 10.1038/s41598-024-63356-6. Sci Rep. 2024. PMID: 38834753 Free PMC article.
Abstract
We previously reported that asthma prevalence was higher in the United States (US) compared to Mexico (MX) (25.8% vs 8.4%). This investigation assessed differences in microbial dust composition in relation to demographic and housing characteristics on both sides of the US-MX Border. Forty homes were recruited in the US and MX. Home visits collected floor dust and documented occupants' demographics, asthma prevalence, and housing structure and use characteristics. US households were more likely to have inhabitants who reported asthma when compared with MX households (30% vs 5%) and had significantly different flooring types. The percentage of households on paved roads, with flushing toilets, with piped water and with air conditioning was higher in the US, while dust load was higher in MX. Significant differences exist between countries in the microbial composition of the floor dust. Dust from US homes was enriched with Geodermatophilus, whereas dust from Mexican homes was enriched with Alishewanella and Chryseomicrobium. A predictive metagenomics analysis identified 68 significantly differentially abundant functional pathways between US and MX. This study documented multiple structural, environmental, and demographic differences between homes in the US and MX that may contribute to significantly different microbial composition of dust observed in these two countries.
Conflict of interest statement
Competing interests Benton, L., Lopez-Galvez, N., Caporaso, JG., Herman, C., Cope E.K., Gameros, M., Rosales, C., Wright, A., Beamer, P., Lothrop, N., declares that they have no financial interests. Carr, T., has received consulting and advisory work for AstraZeneca, GlaxoSmithKline, Genentech, Novartis and royalties for writing from WoltersKluwer (UptoDate). Martínez, F., declares the following grants NIH: HL139054, HL130045, HL132523, HL147016, AI135108, AI146131, AI148104, AI149754, AI176305, HD104618, UH30OD023282; OM PHARMA: UANLID46205; American Lung Association: LTR DTD 4/12/16; and consultancy with OM PHARMA
Figures
References
Publication types
Grants and funding
- UH3 HL147016/HL/NHLBI NIH HHS/United States
- R21 AI176305/AI/NIAID NIH HHS/United States
- P30 ES006694/ES/NIEHS NIH HHS/United States
- R01 AI146131/AI/NIAID NIH HHS/United States
- R01 AI149754/AI/NIAID NIH HHS/United States
- R01 HD104618/HD/NICHD NIH HHS/United States
- P01 AI148104/AI/NIAID NIH HHS/United States
- UG1 HL139054/HL/NHLBI NIH HHS/United States
- U01 HL130045/HL/NHLBI NIH HHS/United States
- UH3 OD023282/OD/NIH HHS/United States
- UG3 HL147016/HL/NHLBI NIH HHS/United States
- R01 HL132523/HL/NHLBI NIH HHS/United States
- R01 AI135108/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
